The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Recent studies have demonstrated that patients with throat-related reflux often require twice
daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once
daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump
inhibitor requiring only once-daily dosing, it may provide laryngopharyngeal reflux (LPR)
symptomatic relief comparable to that of twice daily dosing, yet be more readily approved by
third party payers because of its once daily dosing requirements. It is hypothesized that, in
patients with pharyngeal-probe proven throat reflux, there will be significantly greater
improvement in symptoms and pharyngeal probe findings in those patients receiving
dexlansoprazole than those receiving placebo alone.